Victoria Johnson

The follow-up TRAILBLAZER-EXT and broader population TRAILBLAZER-ALZ 2 studies are currently ongoing.

Andrea Quattrone, MD, discusses how his team worked to create a simpler biomarker after developing MRPI 2.0.

Erenumab also demonstrated improvements in standard measures of efficacy, such as monthly migraine days.

Women with HDP were found to perform worse on cognitive tests 15 years after delivery than their counterparts.

Neurological disability, as assessed by EDSS, was also found to be associated with higher levels of MS fatigue.

A recent analysis of UnitedHealthcare insurance claims revealed increases of almost 200% for some services between 2001 and 2016.

Researchers from Northwestern University found nilotinib had an acceptable safety profile, but lacked efficacy that would encourage further study in patients with Parkinson disease.

Both ongoing ACT-AD and LIFT-AD studies are assessing Athira’s investigational therapy ATH-1017.

Researchers from the University of Turin also found that an NEFH variant showed a protective association with ALS.

PTC Therapeutics announced the initiation of its third study of 2020 investigating vatiquinone.

Annual reviews of moderate to vigorous physical activity may help patients maintain adequate levels of activity after stroke.

More patients on rimegepant than placebo reached at least a 50% reduction in monthly migraine days.

All 7 predictive scales analyzed were found to be highly accurate, with some more feasible than others.

The associations, while modest, were not strong enough to be accurately used as predictors of outcome, but the findings offer value for pediatric care.

Results from the post-hoc analysis, funded by Mitsubishi Tanabe Pharma America, were recently announced.

These data follow a recent announcement from Sio Gene Therapies that the first patient in the high-dose cohort has been dosed.

Efficacy was observed in patients with DEEs such as West Syndrome, Lennox-Gastaut syndrome, and Dravet syndrome.

Patients with any presence of small vessel disease had a 2-times greater risk of recurrent ischemic stroke than those without.

The novel gold nanocrystal suspension has also been shown to remyelinate chronic MS lesions.

Stephen Krieger, MD, discusses a new phase 3 trial of nabiximols, which is now recruiting patients with MS.

MDS-UPDRS score improvements from baseline were significantly greater in patients using the Personal KinetiGraph.

Seizure reduction was observed to be sustained for up to 192 weeks in the Expanded Access Program data.

No cognitive improvements were observed for exercise versus waitlist groups of cognitively normal patients with MS.

The US Early Access Program for fenfluramine allowed access to the treatment for patients who were ineligible for clinical trials.

Microburst stimulation was also found to be more tolerable than standard stimulation in patients with drug-resistant epilepsy.

The registry is planning to expand, with 5 additional centers recently agreeing to participate and institutional research ethics applications underway.

Data from this post-hoc analysis show slight differences between repeated administration of 1 and 2 doses of midazolam.

The data suggest that some patients with partial-onset seizures may benefit from lower doses to mitigate treatment emergent adverse events, but these must be tailored to each patient.

Top line results from the retrospective EXPERIENCE study of brivaracetam are expected to read out in early 2021.

High compliance rates and well-tolerance of perampanel indicate its efficacy as a treatment for partial onset seizures.